Medicare Part D Win Adds 9M Lives to TONMYA Coverage as Tonix Bolsters Sales Force

summarizeSummary

Tonix Pharmaceuticals has secured a new Medicare Part D payer agreement for TONMYA, adding 9 million covered lives and pushing total expected coverage to 145 million lives by January 2027. The company is also expanding its sales force by 50 representatives.

check_boxKey Events · Product Development and Regulatory · TNXP

• Medicare Part D Coverage Secured

  A new PBM agreement adds ~9M Medicare Part D lives, effective Jan 1, 2027, bringing total expected TONMYA coverage to ~145M lives (46% of U.S. covered lives).

• Sales Force Expansion Underway

  By mid-Q3 2026, 50 new sales representatives will be deployed, increasing the total field force to approximately 150 to support TONMYA's commercial launch.

• Commercial Access Milestone

  Combined with two prior GPO agreements and Medicaid in most states, this agreement significantly broadens patient access and revenue potential for the company's lead product.

• Going-Concern Context

  The expanded coverage and sales force directly address the company's going-concern warning by accelerating TONMYA's commercial ramp and cash flow generation.

auto_awesomeAnalysis · TNXP · Life Sciences

A new pharmacy benefit manager agreement will extend TONMYA coverage to approximately 9 million Medicare Part D lives starting January 1, 2027. When combined with earlier commercial and Medicaid wins, total covered lives are projected to reach about 145 million—46% of all U.S. covered lives. To support the launch, the company is adding 50 sales representatives, bringing the field force to roughly 150 by mid-third quarter 2026. This milestone meaningfully expands commercial access for the flagship fibromyalgia drug and directly mitigates going-concern risk by accelerating the revenue trajectory.